Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025
Company Drug

China Resources Double-Crane Pharmaceutical Co., Ltd Receives NMPA Approval for Generic Purinethol

Fineline Cube Feb 11, 2025

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received marketing approval...

Company Drug

Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer

Fineline Cube Feb 11, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...

Company Drug

Bayer Files for Eylea 8 mg EMA Approval to Extend AMD, DME Treatment Intervals

Fineline Cube Feb 11, 2025

Bayer (ETR: BAYN) has submitted a marketing application to the European Medicines Agency (EMA) for...

Company Drug

Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study

Fineline Cube Feb 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...

Company Drug

CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors

Fineline Cube Feb 11, 2025

China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...

Company Drug

Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study

Fineline Cube Feb 11, 2025

German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...

Company Drug

CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma

Fineline Cube Feb 11, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...

Company Drug

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

Fineline Cube Feb 11, 2025

China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...

Company Drug

Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China

Fineline Cube Feb 11, 2025

Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...

Company Deals

R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech

Fineline Cube Feb 11, 2025

Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...

Company Deals

Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market

Fineline Cube Feb 10, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...

Company Drug

Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials

Fineline Cube Feb 10, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...

Company Drug

CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient

Fineline Cube Feb 10, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...

Company

Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations

Fineline Cube Feb 10, 2025

Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...

Company Drug

Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA

Fineline Cube Feb 10, 2025

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...

Company Drug Hospital

Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy

Fineline Cube Feb 10, 2025

The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...

Company Deals

Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs

Fineline Cube Feb 10, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...

Policy / Regulatory

NMPA’s New Guidelines for Drug Registration Review

Fineline Cube Feb 10, 2025

A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...

Policy / Regulatory

Shanghai’s Three-Year Plan to Boost Elderly Care Quality

Fineline Cube Feb 10, 2025

A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...

Posts pagination

1 … 152 153 154 … 603

Recent updates

  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.